Viewing data from:

PENCICLOVIR

ANDA

PENCICLOVIR | A212368 | PADAGIS ISRAEL PHARMACEUTICALS LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: DENAVIR(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Penciclovir (2023)

Total Spending

$3.2M

Total Claims

4,736

Beneficiaries

3,267

Avg Cost/Unit

$112.57

Spending Trend

$203K(2022)→$3.2M(2023)

YoY Change:-9.7%

5yr CAGR:-9.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain7 active DMFs1 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

SMS PHARMACEUTICALS LTDPENCICLOVIR

DMF 297242015

ZHEJIANG CHARIOTEER PHARMACEUTICAL CO LTDPENCICLOVIR (API)

DMF 307582016

CHEMWERTH INCPENCICLOVIR

DMF 332602018

API PHARMA TECH LLCPENCICLOVIR

DMF 345142020

ALEMBIC PHARMACEUTICALS LTDPENCICLOVIR

DMF 350322020

MAITHRI DRUGS PRIVATE LTDPENCICLOVIR

DMF 352432020

TORRENT PHARMACEUTICALS LTDPENCICLOVIR

DMF 364102021

MYLAN LABORATORIES LTDInactivePENCICLOVIR

DMF 343752019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 1%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Sep 27, 2024

No patent or exclusivity listings for this strength.